BBH241220C154000
- 0.00
- 0.000.00%
VanEck Biotech ETF Newsroom
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Press Release: VanEck Announces Year-End Distributions for VanEck Equity ETFs
VanEck Biotech ETF To Go Ex-Dividend On December 23rd, 2024 With 1.2517 USD Dividend Per Share
December 20th (Eastern Time) - $VanEck Biotech ETF(BBH.US)$ is trading ex-dividend on December 23rd, 2024.Shareholders of record on December 23rd, 2024 will receive 1.2517 USD dividend per share on
Traders Fight The Grinch To Save The Santa Rally: 10 S&P 500 Stocks Poised For A Year-End Surge
Vertex Announces U.S. FDA Approval For TRIKAFTA To Include Additional Non-F508del TRIKAFTA-Responsive Variants
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
What's Going On With Amgen Stock On Friday?
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $520
J.P. Morgan's Top Healthcare Stocks for 2025
Why Is Novo Nordisk Crashing After Data for Next-gen Weight Loss Drug?
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Amgen Shares Are Trading Higher. Weight-loss Related Stocks Are up on Friday Following Weaker-than-expected Data From Competitor Lilly.
Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold
The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.
The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.
BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164
Biogen Analyst Ratings